Sign in or create an account to add this stock to your watchlist.
About Supernus Pharmaceuticals (NASDAQ:SUPN)
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:SUPN
CUSIP86845910
Phone301-838-2500
Debt
Debt-to-Equity Ratio0.90
Current Ratio4.90
Quick Ratio4.74
Price-To-Earnings
Trailing P/E Ratio44.80
Forward P/E Ratio30.13
P/E GrowthN/A
Sales & Book Value
Annual Sales$302.24 million
Price / Sales9.81
Cash Flow$1.5158 per share
Price / Cash37.77
Book Value$6.79 per share
Price / Book8.43
Profitability
EPS (Most Recent Fiscal Year)$1.26
Net Income$57.28 million
Net Margins21.89%
Return on Equity30.18%
Return on Assets16.76%
Miscellaneous
Employees422
Outstanding Shares51,800,000
Supernus Pharmaceuticals (NASDAQ:SUPN) Frequently Asked Questions
What is Supernus Pharmaceuticals' stock symbol?
Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."
How were Supernus Pharmaceuticals' earnings last quarter?
Supernus Pharmaceuticals (NASDAQ:SUPN) announced its quarterly earnings results on Tuesday, February, 27th. The specialty pharmaceutical company reported $0.44 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.26 by $0.18. The specialty pharmaceutical company had revenue of $88.44 million for the quarter, compared to analyst estimates of $87.84 million. Supernus Pharmaceuticals had a net margin of 21.89% and a return on equity of 30.18%. View Supernus Pharmaceuticals' Earnings History.
When is Supernus Pharmaceuticals' next earnings date?
What price target have analysts set for SUPN?
10 brokers have issued 12-month price objectives for Supernus Pharmaceuticals' shares. Their predictions range from $41.00 to $66.00. On average, they anticipate Supernus Pharmaceuticals' stock price to reach $53.20 in the next year. View Analyst Ratings for Supernus Pharmaceuticals.
What are Wall Street analysts saying about Supernus Pharmaceuticals stock?
Here are some recent quotes from research analysts about Supernus Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. " (5/5/2018)
- 2. FBR & Co analysts commented, "We are initiating coverage of Supernus Pharmaceuticals (SUPN) with a Buy rating and a 12-month price target of $53 per share. We see strong revenue growth exceeding 25% per year for 2017–2019 with in-line drugs Trokendi XR (epilepsy/ migraine) and Oxtellar XR (epilepsy) driving growth. Starting in 2020, we expect contribution from late-stage pipeline drugs SPN-812, which is a non-stimulant ADHD drug, and SPN-810 for impulsive aggression. We model EPS at $1.05 in 2017, $1.70 in 2018, and $2.35 in 2019 including a full tax rate. Our 2017 EPS estimate compares unfavorably to 2016, which included a tax benefit of $40.8 million or ~$0.80 per share. Our price target averages our DCF valuation and a P/E-derived target, which is 35x 2018E EPS of $1.70 discounted to present at 10%. At current prices, the shares have corrected by ~18% from all-time highs after an update on pipeline drug SPN-810 raised risks on timing/approvability. We see this drop as an opportunity to establish positions." (10/19/2017)
- 3. Cantor Fitzgerald analysts commented, "Interim look at SPN-810 Phase 3 program leads to elimination of the low dose. SUPN announced that an interim analysis of the ongoing Phase 3 trials (CHIME 1 and CHIME 2) in impulsive aggression (IA) resulted in the decision to discontinue the low dose arm, 18mg daily, and randomization of future clinical trial subjects to receive either placebo or 36mg per day." (9/19/2017)
Who are some of Supernus Pharmaceuticals' key competitors?
Some companies that are related to Supernus Pharmaceuticals include Perrigo (PRGO), BeiGene (BGNE), Jazz Pharmaceuticals (JAZZ), Alnylam Pharmaceuticals (ALNY), Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Loxo Oncology (LOXO), Dr. Reddy's Laboratories (RDY) and Taro Pharmaceutical Industries (TARO).
Who are Supernus Pharmaceuticals' key executives?
Supernus Pharmaceuticals' management team includes the folowing people:
- Mr. Jack A. Khattar, Founder, Pres, CEO, Sec. & Director (Age 57)
- Mr. Gregory S. Patrick, VP & CFO (Age 67)
- Dr. Padmanabh P. Bhatt, Chief Scientific Officer and Sr. VP of Intellectual Property (Age 61)
- Mr. Victor L. Vaughn, Sr. VP of Sales and Marketing (Age 60)
- Dr. Stefan K. F. Schwabe, Chief Medical Officer and Exec. VP of R&D (Age 66)
Has Supernus Pharmaceuticals been receiving favorable news coverage?
News articles about SUPN stock have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Supernus Pharmaceuticals earned a coverage optimism score of 0.18 on Accern's scale. They also gave news headlines about the specialty pharmaceutical company an impact score of 47.20 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Supernus Pharmaceuticals' major shareholders?
Supernus Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (13.66%), Summit Trail Advisors LLC (3.12%), Dimensional Fund Advisors LP (2.71%), Champlain Investment Partners LLC (2.46%), Rothschild Asset Management Inc. (2.09%) and Russell Investments Group Ltd. (1.82%). Company insiders that own Supernus Pharmaceuticals stock include Gregory S Patrick, Padmanabh P Bhatt, Stefan KF Schwabe and Victor Vaughn. View Institutional Ownership Trends for Supernus Pharmaceuticals.
Which institutional investors are selling Supernus Pharmaceuticals stock?
SUPN stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., OppenheimerFunds Inc., Millennium Management LLC, Mesirow Financial Investment Management Equity Management, Mckinley Capital Management LLC Delaware, A.R.T. Advisors LLC, Oak Ridge Investments LLC and Envestnet Asset Management Inc.. Company insiders that have sold Supernus Pharmaceuticals company stock in the last year include Gregory S Patrick, Padmanabh P Bhatt, Stefan KF Schwabe and Victor Vaughn. View Insider Buying and Selling for Supernus Pharmaceuticals.
Which institutional investors are buying Supernus Pharmaceuticals stock?
SUPN stock was purchased by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, JPMorgan Chase & Co., BlackRock Inc., Carillon Tower Advisers Inc., Wells Fargo & Company MN, Highbridge Capital Management LLC, Allianz Asset Management GmbH and Allianz Asset Management GmbH. View Insider Buying and Selling for Supernus Pharmaceuticals.
How do I buy shares of Supernus Pharmaceuticals?
Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Supernus Pharmaceuticals' stock price today?
One share of SUPN stock can currently be purchased for approximately $57.25.
How big of a company is Supernus Pharmaceuticals?
Supernus Pharmaceuticals has a market capitalization of $2.85 billion and generates $302.24 million in revenue each year. The specialty pharmaceutical company earns $57.28 million in net income (profit) each year or $1.26 on an earnings per share basis. Supernus Pharmaceuticals employs 422 workers across the globe.
How can I contact Supernus Pharmaceuticals?
Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected]
MarketBeat Community Rating for Supernus Pharmaceuticals (SUPN)
MarketBeat's community ratings are surveys of what our community members think about Supernus Pharmaceuticals and other stocks. Vote "Outperform" if you believe SUPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SUPN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Supernus Pharmaceuticals (NASDAQ:SUPN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
10 Wall Street analysts have issued ratings and price targets for Supernus Pharmaceuticals in the last 12 months. Their average twelve-month price target is $53.20, suggesting that the stock has a possible downside of 7.07%. The high price target for SUPN is $66.00 and the low price target for SUPN is $41.00. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.90 | 2.90 | 2.90 | 2.78 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $53.20 | $51.90 | $51.90 | $49.8889 |
| Price Target Upside: | 7.07% downside | 32.91% upside | 32.91% upside | 30.94% upside |
Supernus Pharmaceuticals (NASDAQ:SUPN) Consensus Price Target History
Supernus Pharmaceuticals (NASDAQ:SUPN) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
Supernus Pharmaceuticals (NASDAQ:SUPN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Supernus Pharmaceuticals (NASDAQ SUPN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.20%
Institutional Ownership Percentage: 97.29%
Supernus Pharmaceuticals (NASDAQ SUPN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/15/2018 | Padmanabh P Bhatt | VP | Sell | 7,868 | $57.93 | $455,793.24 | 7,868 |  |
| 5/11/2018 | Padmanabh P Bhatt | VP | Sell | 67,132 | $53.11 | $3,565,380.52 | 32,500 | |
| 4/19/2018 | Victor Vaughn | VP | Sell | 17,850 | $47.93 | $855,550.50 | 15,594 | |
| 4/5/2018 | Victor Vaughn | VP | Sell | 60,000 | $45.33 | $2,719,800.00 | 24,344 | |
| 1/22/2018 | Padmanabh P Bhatt | VP | Sell | 20,000 | $48.04 | $960,800.00 | 32,500 | |
| 1/17/2018 | Padmanabh P Bhatt | VP | Sell | 20,000 | $44.98 | $899,600.00 | 32,500 | |
| 1/12/2018 | Victor Vaughn | VP | Sell | 5,750 | $45.03 | $258,922.50 | 15,094 | |
| 1/11/2018 | Gregory S. Patrick | CFO | Sell | 50,000 | $43.56 | $2,178,000.00 | | |
| 1/9/2018 | Victor Vaughn | VP | Sell | 15,000 | $42.04 | $630,600.00 | 24,344 | |
| 1/2/2018 | Victor Vaughn | VP | Sell | 55,000 | $40.11 | $2,206,050.00 | | |
| 9/8/2017 | Gregory S. Patrick | CFO | Sell | 50,000 | $47.60 | $2,380,000.00 | | |
| 9/8/2017 | Padmanabh P Bhatt | SVP | Sell | 5,000 | $49.86 | $249,300.00 | 12,500 | |
| 9/7/2017 | Stefan K.F. Schwabe | Insider | Sell | 95,000 | $46.59 | $4,426,050.00 | | |
| 8/16/2017 | Padmanabh P Bhatt | VP | Sell | 3,709 | $45.23 | $167,758.07 | 17,500 | |
| 7/12/2017 | Padmanabh P Bhatt | VP | Sell | 3,735 | $44.90 | $167,701.50 | 21,209 | |
| 6/23/2017 | Padmanabh P Bhatt | VP | Sell | 2,556 | $44.90 | $114,764.40 | 24,944 | |
| 6/2/2017 | Padmanabh P Bhatt | VP | Sell | 10,000 | $39.86 | $398,600.00 | 27,500 | |
| 5/26/2017 | Padmanabh P Bhatt | VP | Sell | 2,500 | $35.90 | $89,750.00 | 37,500 | |
| 5/25/2017 | Padmanabh P Bhatt | VP | Sell | 5,500 | $34.90 | $191,950.00 | 43,887 | |
| 4/24/2017 | Gregory S Patrick | CFO | Sell | 54,000 | $32.37 | $1,747,980.00 | 54,221 | |
| 4/24/2017 | Padmanabh P Bhatt | VP | Sell | 11,806 | $32.59 | $384,757.54 | 45,500 | |
| 9/16/2016 | Gregory S Patrick | CFO | Sell | 2,000 | $25.00 | $50,000.00 | 3,616 | |
| 7/14/2016 | Gregory S. Patrick | CFO | Sell | 3,395 | $22.00 | $74,690.00 | | |
| 4/11/2016 | Padmanabh P Bhatt | VP | Sell | 30,762 | $16.49 | $507,265.38 | 57,306 | |
| 12/9/2015 | Padmanabh P. Bhatt | VP | Sell | 14,238 | $14.90 | $212,146.20 | 88,068 | |
| 12/8/2015 | M James Barrett | Director | Sell | 212,970 | $14.56 | $3,100,843.20 | 115,355 | |
| 11/25/2015 | M James Barrett | Director | Sell | 16,179 | $16.35 | $264,526.65 | 73,929 | |
| 11/18/2015 | M James Barrett | Director | Sell | 93,000 | $16.61 | $1,544,730.00 | 73,929 | |
| 11/16/2015 | M James Barrett | Director | Sell | 119,650 | $16.24 | $1,943,116.00 | 73,929 | |
| 11/4/2015 | Padmanabh P Bhatt | VP | Sell | 5,000 | $19.90 | $99,500.00 | 102,306 | |
| 7/16/2015 | Gregory S Patrick | CFO | Sell | 6,217 | $20.00 | $124,340.00 | | |
| 7/13/2015 | Stefan K.F. Schwabe | EVP | Sell | 1,950 | $19.23 | $37,498.50 | | |
| 6/17/2015 | M James Barrett | Director | Sell | 111,881 | $16.39 | $1,833,729.59 | | |
| 6/17/2015 | Scott D Sandell | Major Shareholder | Sell | 136,597 | $16.50 | $2,253,850.50 | | |
| 6/16/2015 | M James Barrett | Director | Sell | 55,105 | $16.85 | $928,519.25 | | |
| 6/16/2015 | Scott D Sandell | Major Shareholder | Sell | 95,437 | $16.92 | $1,614,794.04 | | |
| 6/12/2015 | Stefan K.F. Schwabe | EVP | Sell | 2,051 | $18.27 | $37,471.77 | | |
| 6/11/2015 | Stefan K.F. Schwabe | EVP | Sell | 3,631 | $16.39 | $59,512.09 | | |
| 3/24/2015 | Jones W Bryan | VP | Sell | 1,900 | $12.00 | $22,800.00 | | |
| 8/19/2013 | Padmanabh Bhatt | VP | Sell | 2,285 | $8.21 | $18,759.85 | 51,806 | |
| 3/22/2013 | Michael Bigham | Director | Buy | 35,000 | $5.41 | $189,350.00 | | |
| 3/21/2013 | John M Siebert | Director | Buy | 3,000 | $5.50 | $16,500.00 | | |
| 3/15/2013 | Jack A Khattar | CEO | Buy | 10,000 | $6.15 | $61,500.00 | | |
| 3/14/2013 | Gregory S Patrick | CFO | Buy | 5,000 | $6.95 | $34,750.00 | | |
| 12/4/2012 | John M Siebert | Director | Buy | 7,000 | $8.14 | $56,980.00 | | |
(Data available from 1/1/2013 forward)
Supernus Pharmaceuticals (NASDAQ SUPN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Stifel Nicolaus Raises Supernus Pharmaceuticals (SUPN) Price Target to $60.00
www.americanbankingnews.com - May 25 at 3:47 PM |
 | Supernus Pharmaceuticals (SUPN) PT Raised to $60 at Stifel; Sees More Expansion Opportunity Than Competitive Risk
www.streetinsider.com - May 25 at 8:18 AM |
| Supernus Pharmaceuticals (SUPN) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 24 at 1:47 PM |
| Supernus Pharmaceuticals (SUPN) to Post FY2018 Earnings of $1.77 Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - May 24 at 8:32 AM |
| Supernus Pharmaceuticals Forecasted to Post Q3 2019 Earnings of $0.69 Per Share (SUPN)
www.americanbankingnews.com - May 23 at 7:37 AM |
| Q1 2019 Earnings Estimate for Supernus Pharmaceuticals Issued By Piper Jaffray Companies (SUPN)
www.americanbankingnews.com - May 22 at 7:48 AM |
| Zacks: Brokerages Expect Supernus Pharmaceuticals (SUPN) Will Post Quarterly Sales of $99.30 Million
www.americanbankingnews.com - May 20 at 5:03 AM |
| Supernus Pharmaceuticals (SUPN) Expected to Post Earnings of $0.46 Per Share
www.americanbankingnews.com - May 18 at 5:33 AM |
| Insider Selling: Supernus Pharmaceuticals (SUPN) VP Sells 7,868 Shares of Stock
www.americanbankingnews.com - May 16 at 7:50 PM |
| Supernus Pharmaceuticals (SUPN) Upgraded to "Strong-Buy" by BidaskClub
www.americanbankingnews.com - May 16 at 3:46 PM |
 | Implied Volatility Surging for Supernus (SUPN) Stock Options
finance.yahoo.com - May 15 at 5:49 PM |
| B. Riley Comments on Supernus Pharmaceuticals' Q2 2018 Earnings (SUPN)
www.americanbankingnews.com - May 15 at 8:02 AM |
| Investors Buy High Volume of Supernus Pharmaceuticals Call Options (SUPN)
www.americanbankingnews.com - May 15 at 6:58 AM |
 | Supernus Pharmaceuticals Reaches Analyst Target Price
www.nasdaq.com - May 14 at 5:21 PM |
| Supernus Pharmaceuticals (SUPN) VP Padmanabh P. Bhatt Sells 67,132 Shares
www.americanbankingnews.com - May 14 at 4:19 PM |
| Today’s Research Reports on Stocks to Watch: Intrexon and Supernus Pharmaceuticals
finance.yahoo.com - May 14 at 8:26 AM |
| Jefferies Group Comments on Supernus Pharmaceuticals' Q2 2018 Earnings (SUPN)
www.americanbankingnews.com - May 14 at 1:38 AM |
| Q2 2018 EPS Estimates for Supernus Pharmaceuticals Increased by Analyst (SUPN)
www.americanbankingnews.com - May 14 at 1:38 AM |
| Supernus Pharmaceuticals (SUPN) Upgraded to "Strong-Buy" by ValuEngine
www.americanbankingnews.com - May 12 at 10:39 AM |
| 6 Ways To Play Biotechs As Small Stocks Score Big Gains
finance.yahoo.com - May 11 at 5:58 PM |
| Q3 2018 EPS Estimates for Supernus Pharmaceuticals Cut by Piper Jaffray (SUPN)
www.americanbankingnews.com - May 11 at 10:07 AM |
| Q3 2018 EPS Estimates for Supernus Pharmaceuticals (SUPN) Lowered by SunTrust Banks
www.americanbankingnews.com - May 11 at 10:07 AM |
| Form 10-Q SUPERNUS PHARMACEUTICALS For: Mar 31
www.streetinsider.com - May 11 at 8:25 AM |
| SunTrust Banks Equities Analysts Boost Earnings Estimates for Supernus Pharmaceuticals (SUPN)
www.americanbankingnews.com - May 10 at 8:42 AM |
| Edited Transcript of SUPN earnings conference call or presentation 9-May-18 1:00pm GMT
finance.yahoo.com - May 10 at 8:23 AM |
 | Supernus Pharmaceuticals' (SUPN) CEO, Jack Khattar on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 5:35 PM |
| SunTrust Banks Comments on Supernus Pharmaceuticals' Q1 2018 Earnings (SUPN)
www.americanbankingnews.com - May 9 at 8:23 AM |
| Supernus: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 8:18 AM |
| Supernus Pharmaceuticals (SUPN) Announces Quarterly Earnings Results, Beats Expectations By $0.19 EPS
www.americanbankingnews.com - May 8 at 9:14 PM |
| Supernus Pharmaceuticals beats by $0.16, beats on revenue
seekingalpha.com - May 8 at 5:40 PM |
| Supernus Announces First Quarter 2018 Financial Results and Record Quarterly Revenue
finance.yahoo.com - May 8 at 5:40 PM |
| Supernus Pharmaceuticals (SUPN) Downgraded by BidaskClub
www.americanbankingnews.com - May 8 at 2:28 PM |
| Supernus Pharmaceuticals (SUPN) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 5 at 7:35 PM |
| Analysts Expect Supernus Pharmaceuticals (SUPN) Will Post Quarterly Sales of $87.46 Million
www.americanbankingnews.com - May 2 at 2:40 AM |
| Supernus Pharmaceuticals (SUPN) Expected to Announce Earnings of $0.33 Per Share
www.americanbankingnews.com - April 30 at 5:14 PM |
| Supernus Pharmaceuticals (SUPN) to Release Earnings on Monday
www.americanbankingnews.com - April 30 at 7:23 AM |
| Supernus Pharmaceuticals (SUPN) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 29 at 1:36 PM |
| Supernus to Host First Quarter 2018 Earnings Conference Call
finance.yahoo.com - April 24 at 5:36 PM |
| Insider Selling: Supernus Pharmaceuticals (SUPN) VP Sells 17,850 Shares of Stock
www.americanbankingnews.com - April 20 at 7:22 PM |
| Harry Boxer’s biotech-stock breakouts to watch
finance.yahoo.com - April 19 at 5:40 PM |
| Supernus Pharmaceuticals (SUPN) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - April 18 at 3:33 PM |
| Supernus Pharmaceuticals (SUPN) Downgraded by Piper Jaffray to Neutral
www.americanbankingnews.com - April 17 at 11:58 PM |
| Supernus Pharmaceuticals (SUPN) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 17 at 6:29 PM |
| Supernus Pharmaceuticals (SUPN) Rating Reiterated by Stifel Nicolaus
www.americanbankingnews.com - April 17 at 5:27 PM |
| BidaskClub Downgrades Supernus Pharmaceuticals (SUPN) to Buy
www.americanbankingnews.com - April 16 at 12:19 AM |
| Zacks: Brokerages Expect Supernus Pharmaceuticals (SUPN) Will Post Quarterly Sales of $87.82 Million
www.americanbankingnews.com - April 15 at 2:46 AM |
| Supernus Pharmaceuticals (SUPN) Stock Rating Reaffirmed by Cowen
www.americanbankingnews.com - April 13 at 6:39 PM |
| Zacks: Brokerages Expect Supernus Pharmaceuticals (SUPN) to Announce $0.33 EPS
www.americanbankingnews.com - April 13 at 5:17 PM |
| Form 4 SUPERNUS PHARMACEUTICALS For: Apr 05 Filed by: Vaughn Victor
www.streetinsider.com - April 11 at 5:32 PM |
| Factors of Influence in 2018, Key Indicators and Opportunity within Harmonic, Supernus Pharmaceuticals, America First Multifamily Investors, Ballard Power, ServiceSource International, and Materialise NV — New Research Emphasizes Economic Growth
finance.yahoo.com - April 11 at 8:30 AM |
Supernus Pharmaceuticals (NASDAQ:SUPN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Supernus Pharmaceuticals (NASDAQ:SUPN) Income Statement, Balance Sheet and Cash Flow Statement
Supernus Pharmaceuticals (NASDAQ SUPN) Stock Chart for Friday, May, 25, 2018
Loading chart…
